21.5 C
New York
Wednesday, June 10, 2026

Tag: cellular

newssourceFORcompanyinformationcontent1marketreleases

Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth...

– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT – TORONTO and DALLAS, Aug. 11, 2025 /PRNewswire/ - Perimeter Medical Imaging AI,...

Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth...

– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT – TORONTO and DALLAS, Aug. 11, 2025 /CNW/ - Perimeter Medical Imaging AI,...

Telit Cinterion Enhances deviceWISE® AI Visual Inspection with NVIDIA TAO 6.0 Integration to Improve Industrial IoT Automation

The NVIDIA TAO 6.0 integration delivers advanced foundation models, fine-tuning capabilities, prompt‑based segmentation, and in‑context segmentationManufacturers benefit from enhanced tools for on-premises inferencing and...

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Ad hoc announcement pursuant to Art. 53 LR

LionCare: The Future of Wellness with Terahertz Technology for Restful Sleep and Healing in 2025

Experience Groundbreaking Sleep and Cellular Support Backed by Terahertz Innovation, Trusted by Wellness Experts in 2025 
Experience Groundbreaking Sleep and Cellular Support Backed by Terahertz Innovation, Trusted by Wellness Experts in 2025

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron announces the pricing of a public offering of common stock and warrants.

American Camp Association Supports Texas’ Efforts to Strengthen Camp Safety Standards

MARTINSVILLE, Ind., Aug. 7, 2025 /PRNewswire/ -- In the wake of the tragic July floods that claimed the lives of campers and counselors in...

Millicom (Tigo) Q2 2025 Earnings Release

Millicom (Tigo) Q2 2025 Earnings Release

Millicom (Tigo) declares $2.50 per share interim dividend to be paid in two equal installments on October 15, 2025 and April 15, 2026

Luxembourg, August 6, 2025 – In line with the press release published on June 13, 2025, the Board of Directors of Millicom International Cellular S.A. (“Millicom”) approved the interim dividend of $2.50 per share, to be paid in two equal installments of $1.25 per share on October 15, 2025 and April 15, 2026. Other important dates and information relating to the Interim Dividend are as follows:

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.

OneLayer and Check Point Software Partner to Deliver Context-Based Security for Private Cellular Networks

BOSTON and TEL AVIV, Israel, Aug. 6, 2025 /PRNewswire/ -- OneLayer, the leading provider of private LTE/5G security and device management solutions, and Check...

Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform

HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced it has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance. The clearance expands the use of its RS001 cardio-respiratory wearable to home environments and includes approval for its connected care platform marketed as 1Bio™.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCellular

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers